About Pricing FAQs Providers Trials Blog

Login Get started

Finding studies

Your health journey, clearly organized.

Questions? feedback@clareohealth.com

Product

How it works
Pricing
For Providers
Trials

Company

About
Blog
FAQ

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Search for Predictors of Therapeutic Response in Ovarian Carcinoma

NCT01391351·7 sites·ClinicalTrials.gov

What this study is about

Take this into the appointment.

Saves the questions and what to expect into your notes, next to the visit they belong to.

Keep this study

Lead

Centre Francois Baclesse

Age

18–any

Sex

FEMALE

Healthy volunteers

Not accepted

You may be eligible if

Patients with cancer of the ovary, peritoneum or of the fallopian tube
Stage III or IV
Cancer of serous histology
Patients of any chemotherapy naive
Patients should receive treatment with chemotherapy for first line by Taxol- Carboplatin. Avastin is authorized in concomitant.
An initial surgery or through authorized
Patients who signed informed consent
Patients over the age of 18 years

You may not be if

Patients being treated for another cancer chemotherapy and / or hormone therapy
Patients receiving other chemotherapy Taxol-carboplatin associated or not to avastin
Patients under guardianship
Previous history of pelvic radiotherapy
History of malignancy blood

The record

StatusCompleted

PhaseNo phase

Taking part107

StartedJun 2011

UpdatedJul 21, 2016

Conditions

Carcinoma of the Ovary Fallopian Tube Cancer Peritoneal Serous-type Advanced Stage

Where7

Centre Eugène Marquis
Rennes, Brittany Region, France
Centre François BACLESSE
Caen, Calvados, France
Centre Réné Gauducheau
Nantes, Loire-Atlantique, France

Clareo Health | Search for Predictors of Therapeutic Response in Ovarian Carcinoma